Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar
D Preiss, JA Tobert, GK Hovingh et al.
KEYWORDS
ezetimibe; low-density lipoprotein cholesterol; Mendelian randomization; proprotein convertase subtilisin/kexin type 9; statin